Drug Profile

KF 1601

Alternative Names: KF-1601

Latest Information Update: 19 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmunoForge
Class Antineoplastics
Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Chronic myeloid leukaemia

Highest Development Phases

Preclinical Chronic myeloid leukaemia

Most Recent Events

13 Jun 2024 Pharmacodynamics data from a preclinical trial in Chronic myeloid leukaemia presented at the 29^th Congress of the European Haematology Association (EHA-2024)
13 Jun 2024 ImmunoForge plans a clinical trial in Chronic myeloid leukaemia
28 Feb 2023 No recent reports of development identified for research development in Chronic-myeloid-leukaemia in South Korea

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com